
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. demonstrated a robust financial recovery in the third quarter of 2025, with total revenues reaching $4.22 million, reflecting a significant 105% quarter-over-quarter growth compared to $2.06 million in the previous quarter. Additionally, the company's gross margins improved markedly to 60.3%, up from 39.8% in the second quarter, showcasing enhanced operational efficiency. The announcement of a non-binding merger agreement with Applied Digital Cloud further enhances the company's strategic positioning, potentially driving future growth and value creation.
Bears say
Ekso Bionics Holdings Inc. experienced a revenue miss in the prior quarter, primarily attributed to two order delays in enterprise sales that amounted to $1.5 million. For the third quarter of 2025, the company reported revenues of $4.23 million, which slightly exceeded consensus estimates of $4.16 million; however, it still recorded a significant net loss of $0.54 per share, highlighting ongoing financial challenges. The downgrade to a Neutral rating reflects management's concerns about the company's operational performance and the uncertainty surrounding future sales growth.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares